Chronic delivery of antibody fragments using immunoisolated cell implants as a passive vaccination tool.

Details

Ressource 1Download: BIB_2D8D929616D2.P001.pdf (1643.11 [Ko])
State: Public
Version: author
Serval ID
serval:BIB_2D8D929616D2
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Chronic delivery of antibody fragments using immunoisolated cell implants as a passive vaccination tool.
Journal
Plos One
Author(s)
Marroquin Belaunzaran O., Cordero M.I., Setola V., Bianchi S., Galli C., Bouche N., Mlynarik V., Gruetter R., Sandi C., Bensadoun J.C., Molinari M., Aebischer P.
ISSN
1932-6203 (Electronic)
ISSN-L
1932-6203
Publication state
Published
Issued date
2011
Volume
6
Number
4
Pages
e18268
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov'tPublication Status: epublish
Abstract
BACKGROUND: Monoclonal antibodies and antibody fragments are powerful biotherapeutics for various debilitating diseases. However, high production costs, functional limitations such as inadequate pharmacokinetics and tissue accessibility are the current principal disadvantages for broadening their use in clinic.
METHODOLOGY AND PRINCIPAL FINDINGS: We report a novel method for the long-term delivery of antibody fragments. We designed an allogenous immunoisolated implant consisting of polymer encapsulated myoblasts engineered to chronically release scFv antibodies targeted against the N-terminus of the Aβ peptide. Following a 6-month intracerebral therapy we observed a significant reduction of the production and aggregation of the Aβ peptide in the APP23 transgenic mouse model of Alzheimer's disease. In addition, functional assessment showed prevention of behavioral deficits related to anxiety and memory traits.
CONCLUSIONS AND SIGNIFICANCE: The chronic local release of antibodies using immunoisolated polymer cell implants represents an alternative passive vaccination strategy in Alzheimer's disease. This novel technique could potentially benefit other diseases presently treated by local and systemic antibody administration.
Keywords
Animals, Cell Line, Immunization, Passive, Immunoglobulin Fragments/administration & dosage, Mice
Pubmed
Open Access
Yes
Create date
29/04/2013 9:41
Last modification date
20/08/2019 13:12
Usage data